Sertraline

Generic Name: Sertraline

Brand Names: Zoloft

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₇Cl_₂N

CAS Number: 79617-96-2

Unique Ingredient Identifier: QUC7NX6WMB

Background: Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.

Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.

Indication: Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.

Associated Conditions: Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)

Clinical Trials

Effect of Sertraline on Inflammation in Hemodialysis Patients with Depression: a Randomized Controlled Trial

Not Applicable

Active, not recruiting

Conditions: Inflamation
Hemodialysis
End Stage Renal Disease on Hemodialysis (Diagnosis)

Interventions: Drug: Sertraline (Oral Antidepressant)
Drug: Placebo

First Posted Date: 2025-02-21

Last Posted Date: 2025-03-04

Lead Sponsor: Nishtar Medical University

Target Recruit Count: 62

Registration Number: NCT06840379

Locations: 🇵🇰
Nishtar Hospital, Multan, Multan, Punjab, Pakistan

The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

Phase 3

Not yet recruiting

Conditions: Major Depressive Disorder (MDD)

Interventions: Drug: Ammoxetine
Drug: Placebo
Drug: Sertraline

First Posted Date: 2025-02-14

Last Posted Date: 2025-02-14

Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Target Recruit Count: 770

Registration Number: NCT06827431

Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.

Not Applicable

Recruiting

Conditions: Gut-Brain Disorders
GERD Without Erosive Esophagitis

Interventions: Drug: Imipramine Pill
Drug: Zoloft 50Mg Tablet
Drug: Takepron

First Posted Date: 2025-01-16

Last Posted Date: 2025-01-27

Lead Sponsor: Hualien Tzu Chi General Hospital

Target Recruit Count: 610

Registration Number: NCT06778824

Locations: 🇨🇳
Hualien Tzu Chi Hospital,Buddhist Tzu Chi Medical Foundation, Hualien City, Taiwan

A Non-randomized Controlled Trial Was Conducted to Observe the Improvement in the Level of HAMA in Patients With Generalized Anxiety Disorder During the 6-week Period of Oral Treatment With Chaihu Jia Longgu Muli Tang (Bupleurum Plus Dragon Bone and Oyster Shell Decoction) Combined With Sertraline.

Not Applicable

Completed

Conditions: Generalised Anxiety Disorder

Interventions: Drug: Bupleurum Plus Dragon Bone and Oyster Shell Decoction Combined with Sertraline
Drug: Sertraline Hydrochloride Tablets

First Posted Date: 2024-12-10

Last Posted Date: 2024-12-10

Lead Sponsor: Lin Xiaoqian

Target Recruit Count: 205

Registration Number: NCT06725771

Locations: 🇨🇳
Jiangsu Province Hospital of TCM Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

Phase 4

Recruiting

Conditions: Premenstrual Dysphoric Disorder (PMDD)

Interventions: Drug: sertraline 50 mg daily
Drug: Placebo Oral Tablet

First Posted Date: 2024-11-26

Last Posted Date: 2025-05-14

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 288

Registration Number: NCT06704594

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Reproductive Mental Health Center, Baltimore, Maryland, United States

Efficacy of Statins Among Major Depressive Disorder

Phase 3

Recruiting

Conditions: Major Depressive Disorder
MDD

Interventions: Drug: Sertraline Pill
Drug: Rosuvastatin 10 mg tablet.

First Posted Date: 2024-11-21

Last Posted Date: 2024-11-21

Lead Sponsor: Ain Shams University

Target Recruit Count: 145

Registration Number: NCT06698666

Locations: 🇪🇬
El demerdash hospital, Cairo, Al abbasia, Egypt

ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial

Phase 2

Not yet recruiting

Conditions: Depression

Interventions: Drug: Guanfacine
Drug: Sertraline

First Posted Date: 2024-05-10

Last Posted Date: 2024-12-02

Lead Sponsor: Stanford University

Target Recruit Count: 160

Registration Number: NCT06408246

Locations: 🇺🇸
Stanford Psychiatry and Behavioral Sciences Department, Palo Alto, California, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States